Zynerba Pharmaceuticals Inc (ZYNE.OQ)
ZYNE.OQ on NASDAQ Stock Exchange Global Market
3.75USD
31 Jul 2020
3.75USD
31 Jul 2020
Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$3.75
$3.75
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
15
15
Avg. Vol
333,470
333,470
52-wk High
$12.51
$12.51
52-wk Low
$2.55
$2.55
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.43 | December | 3 Aug 2020 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 2 | 2 | 2 | 2 |
| (2) OUTPERFORM | 3 | 4 | 4 | 4 |
| (3) HOLD | 2 | 1 | 1 | 1 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 1.86 | 1.86 | 1.86 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 6 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-20 | 6 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 7 | 0.00 | 0.00 | 0.00 | 5.20 |
| Year Ending Dec-21 | 7 | 2.86 | 20.00 | 0.00 | 62.93 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | 7 | -0.43 | -0.36 | -0.51 | -0.50 |
| Quarter Ending Dec-20 | 7 | -0.42 | -0.24 | -0.50 | -0.50 |
| Year Ending Dec-20 | 7 | -1.80 | -1.43 | -1.97 | -1.65 |
| Year Ending Dec-21 | 7 | -1.52 | -1.18 | -2.10 | -0.02 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-20 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-20 | -0.50 | -0.53 | 0.03 | -6.62 |
| Quarter Ending Dec-19 | -0.50 | -0.46 | 0.04 | -8.53 |
| Quarter Ending Sep-19 | -0.52 | -0.44 | 0.08 | -15.60 |
| Quarter Ending Jun-19 | -0.50 | -0.50 | 0.00 | -0.66 |
| Quarter Ending Mar-19 | -0.49 | -0.47 | 0.02 | -3.75 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-20 | 0.00 | 0.00 | 0.00 | 0.00 | 5.20 |
| Year Ending Dec-21 | 2.86 | 2.86 | 15.54 | 15.50 | 62.93 |
| Earnings (per share) | |||||
| Quarter Ending Sep-20 | -0.43 | -0.43 | -0.42 | -0.42 | -0.50 |
| Quarter Ending Dec-20 | -0.42 | -0.42 | -0.44 | -0.43 | -0.50 |
| Year Ending Dec-20 | -1.80 | -1.80 | -1.81 | -1.80 | -1.65 |
| Year Ending Dec-21 | -1.52 | -1.52 | -1.71 | -1.60 | -0.02 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-20 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-20 | 0 | 0 | 0 | 0 |
| Year Ending Dec-21 | 0 | 0 | 0 | 5 |
| Earnings | ||||
| Quarter Ending Sep-20 | 0 | 0 | 1 | 3 |
| Quarter Ending Dec-20 | 0 | 0 | 3 | 1 |
| Year Ending Dec-20 | 0 | 0 | 3 | 1 |
| Year Ending Dec-21 | 0 | 0 | 4 | 1 |
Earnings vs. 
Estimates- Zynerba's cannabis-based drug for rare genetic disorder fails study
- Zynerba's cannabis-based drug for rare genetic disorder fails study
- UPDATE 1-Zynerba's cannabis-based drug for rare genetic disorder fails study
- BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel
- Zynerba's cannabis-based drug for rare genetic disorder fails study